Literature DB >> 2703969

Dose dependency of furosemide-induced sodium excretion.

F Andreasen1, I N Lauridsen, F A Hansen, S Christensen, E Steiness.   

Abstract

Intravenous furosemide doses ranging from 5 to 120 mg were given to healthy young volunteers with and without individualized active rehydration with a sodium chloride solution. Sodium excretion rates and fractional sodium excretions (FENa) percentages were correlated significantly with dose and with urinary excretion rates of furosemide. The ED50 was below 5 mg and no additional natriuretic effect was seen above 40 mg. The efficiency (FENa percentage per microgram of furosemide excreted per minute during a certain clearance period) was dependent on hydration and on time. For the period 15 to 30 min a significant linear relationship between furosemide dose and the reciprocal of the efficiency indicated a higher efficiency for lower doses and a theoretical maximal value of FENa of 0.4% per micrograms of furosemide excreted per minute. A relative value for a dose-dependent efficiency reduction was calculated for each dose. The ED50 for dose-dependent efficiency reduction was about 12 mg i.v. Simultaneous measurements of lithium clearance indicated a proximal site of action for furosemide which was saturated at furosemide excretion rates above 50 micrograms/minute. For the major, distal, site of action no maximal value was demonstrated. It is concluded that a wanted balance between a strong natriuretic effect and weak sodium retaining mechanism not necessarily is achieved by a high dose and that information concerning that problem must be obtained from studies in relevant patient groups.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703969

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.

Authors:  Simon B Dimmitt; Hans G Stampfer; Jennifer H Martin; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

Review 2.  Why maximum tolerated dose?

Authors:  Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

Review 3.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

4.  Analysis of the natriuretic action of a loop diuretic, piretanide, in man.

Authors:  F H Noormohamed; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

5.  Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency.

Authors:  R W van Olden; J J van Meyel; P G Gerlag
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Increased expression of renal TRPM6 compensates for Mg(2+) wasting during furosemide treatment.

Authors:  Annelies A van Angelen; AnneMiete W van der Kemp; Joost G Hoenderop; René J Bindels
Journal:  Clin Kidney J       Date:  2012-11-07

7.  Effect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration: A Randomized Controlled Trial.

Authors:  Boris Zingerman; Michal Herman-Edelstein; Arie Erman; Sarit Bar Sheshet Itach; Yaacov Ori; Benaya Rozen-Zvi; Uzi Gafter; Avry Chagnac
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.